scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "MULTIPLE myeloma"

1 - 10 of 78,305 results for
 "MULTIPLE myeloma"
Results per page:

MM-192 Young Patients With Multiple Myeloma Diagnosed Before 50 Years of Age: Single-Center Experience.

Publication Type: Academic Journal

Source(s): Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Oct; Vol. 22 Suppl 2, pp. S412-S413.

Abstract: Context: Multiple myeloma is a disease of older adults, and there are conflicting data about the presentation, treatment, and prognosis in younger age groups.Objective: The present study is designed to analyze the clinical and hematological profile and...

View details

CT-511 Clinical Characteristics and Response Outcomes in Older Multiple Myeloma Patients Who Received Idecabtagene Vicleucel: A Single Center Study.

Publication Type: Academic Journal

Source(s): Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Oct; Vol. 22 Suppl 2, pp. S446.

Abstract: Context: Multiple myeloma (MM) is a disease of older adults with a median age of 69y at the time of diagnosis. Older patients remain at higher risk for poor outcomes due to physical and physiological decline with aging.Objectives: To study clinical cha...

View details

Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smouldering myeloma patients to prevent development of end-organ damage.

Publication Type: Academic Journal

Source(s): British journal of haematology [Br J Haematol] 2022 Oct; Vol. 199 (1), pp. 65-75. Date of Electronic Publication: 2022 May 24.

Abstract: The definition of multiple myeloma (MM) was updated in 2014, with the intent to enable earlier treatment and thereby avoid appearance of end-organ damage at progression from smouldering multiple myeloma (SMM) to MM. The purpose of this study was to inv...

View details

Smoldering multiple myeloma: Reviewing the rationale for intervention.

Publication Type: Academic Journal

Source(s): Leukemia & lymphoma [Leuk Lymphoma] 2022 Sep; Vol. 63 (9), pp. 2033-2040. Date of Electronic Publication: 2022 May 09.

Authors:

Abstract: Smoldering multiple myeloma has been recognized for over 40 years and represents a pre-symptomatic phase of the 2nd most common hematologic malignancy. 1/3 of patients will remain asymptomatic at 10 years. There is an identifiable subset of patients th...

View details

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.

Publication Type: Academic Journal

Source(s): Cancer cell [Cancer Cell] 2022 Nov 14; Vol. 40 (11), pp. 1358-1373.e8.

Abstract: Patients with smoldering multiple myeloma (SMM) are observed until progression, but early treatment may improve outcomes. We conducted a phase II trial of elotuzumab, lenalidomide, and dexamethasone (EloLenDex) in patients with high-risk SMM and perfor...

View details

MM-219 Smoldering Multiple Myeloma: A Demographic and Survival Analysis of a Retrospective Cohort Study in a University Hospital of Buenos Aires.

Publication Type: Academic Journal

Source(s): Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Oct; Vol. 22 Suppl 2, pp. S414-S415.

Abstract: Introduction: Smoldering multiple myeloma (SMM) is a heterogeneous asymptomatic precursor to multiple myeloma (MM). It is the intermediate stage between monoclonal gammopathy of undetermined significance (MGUS) and MM, where there is a subset of patien...

View details

Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.

Publication Type: Academic Journal

Source(s): European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Oct; Vol. 174, pp. 243-250. Date of Electronic Publication: 2022 Sep 05.

Abstract: Background: Smoldering multiple myeloma (SMM) is a heterogeneous disease in terms of progression to myeloma (MM), but its standard of care continues to be observation.Methods: The QuiRedex phase 3 trial initiated in 2007 included 119 high-risk patients...

View details

[A novel cause of acute kidney injury in multiple myeloma: Lenalidomide-induced acute interstitial nephritis].

Publication Type: Academic Journal

Source(s): Nephrologie & therapeutique [Nephrol Ther] 2022 Nov; Vol. 18 (6), pp. 565-569. Date of Electronic Publication: 2022 Jul 30.

Abstract: Introduction: Lenalidomide is an immunomodulatory drug widely used in the treatment of multiple myeloma. Several cases of nephrotoxicity have been reported, but few have been documented histologically.Case Presentation: We report a case of acute inters...

View details

Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.

Publication Type: Academic Journal

Source(s): Blood advances [Blood Adv] 2022 Nov 22; Vol. 6 (22), pp. 5873-5883.

Abstract: Early alterations within the bone marrow microenvironment that contribute to the progression of multiple myeloma (MM) from its precursor stages could be the key to identifying novel therapeutic approaches. However, the intrinsic variability in cellular...

View details

A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis.

Publication Type: Academic Journal

Source(s): BMC nephrology [BMC Nephrol] 2022 Nov 17; Vol. 23 (1), pp. 370. Date of Electronic Publication: 2022 Nov 17.

Abstract: Background: Multiple myeloma (MM) is a malignant neoplasm associated with kidney involvement in nearly half of the patients. Cast nephropathy, monoclonal immunoglobulin deposition disease (MIDD), and light chain (AL) amyloidosis are the most common mon...

View details
sponsored